Human Islet Research Network Consortium on Targeting and Regeneration (HIRN-CTAR)
January 2022 Council
Point(s) of Contact
Olivier Blondel, Ph.D.
This Funding Opportunity Announcement (FOA) will solicit new applications to the Consortium on Targeting and Regeneration (CTAR) that will continue to support the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication, islet cell plasticity, in-vivo reprogramming of pancreatic non-beta cells into beta-like cells, and protection of the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN) and this initiative would represent the second renewal of the CTAR effort (CTAR 3.0). In the past six years, the consortium has made significant progress toward its long-term goals. Renewed support is needed to bring the islet targeting strategies and islet-specific therapeutic solutions that are currently being developed closer to clinical applications, and to encourage the development of additional strategies to increase or protect beta cell mass in patients with T1D.